[Skip to Content]
Navigation
Home > Medical Directory > Scleroderma Symptoms > Lung Involvement > Pulmonary Hypertension

Prognosis of Pulmonary Hypertension in Systemic Sclerosis

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Overview of PH Prognosis
Functional Classification of PH
Markers for Prognosis of PH
Personal Stories of Prognosis of PH

Overview of Prognosis of Pulmonary Hypertension in Systemic Sclerosis (Scleroderma)

Early diagnosis and treatment substantially improves the prognosis for pulmonary hypertension associated with systemic sclerosis (scleroderma). (Also see: Types of Scleroderma, PH Diagnosis, PH Treatments and Types of Scleroderma: Prognosis and Mortality)
Prediction of pulmonary complications and long term survival in systemic sclerosis (SSc). This study provides data on long-term outcome of SSc and the timing and frequency of major organ complications. PubMed, Arthritis Rheumatol, 03/03/2014. (Also see: Pulmonary Involvement)
Left Ventricular Ejection Time (LVET) in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure. Chest. 2013;144(5):1512-1520.
Survival in systemic sclerosis(SSc)-associated pulmonary arterial hypertension (PAH) in the modern management era. SSc-associated PAH remains a devastating disease and age, male gender, and cardiac index were the main prognosis factors. Early detection of less severe patients should be a priority. PubMed, Ann Rheum Dis, 2013 Dec 1;72(12):1940-6.
Survival remains poor for systemic sclerosis-associated pulmonary hypertension. Despite the frequent assertion that survival has improved in recent years for patients who have pulmonary hypertension associated with systemic sclerosis, a meta-analysis that allowed pooling of data from numerous small studies shows otherwise. Rheumatology News, 09/05/2013.
Survival in Systemic Sclerosis with Pulmonary Arterial Hypertension Has Not Improved in the Modern Era. Despite an improvement in clinical status, unlike patients with pulmonary arterial hypertension, the mortality in systemic sclerosis has not improved since the introduction of epoprostenol. CHEST Journal, June 6 2013. (Also see: Flolan/Prostacyclin/Epoprostenol)
Survival and prognostic factors in systemic sclerosis (SSc)-associated pulmonary hypertension (PAH). This analysis confirms a poor pooled 3-year survival rate of 52% (47-58) in SSc-associated PH. PubMed, Arthritis Rheum, 2013 Jun 5.
Demographics and Outcomes of Patients Diagnosed With Pulmonary Hypertension (PAH) With Pulmonary Capillary Wedge Pressures (PCWP) 16 to 18 mm Hg. Insights from the REVEAL Registry. Patients with PCWP 16 to 18 mm Hg who were diagnosed and treated for PAH were older, heavier, and more likely to have comorbidities associated with left ventricular diastolic dysfunction. Five-year survival rates were similarly low for all PCWP subgroups. CHEST,January 2013, Vol 143, No. 1 (Also see: REVEAL Registry)
Epidemiology and risk factors for pulmonary hypertension (PH) in systemic sclerosis (SSc). The ultimate objective in understanding the risk of developing PH in SSc is early diagnosis and early initiation of appropriate therapy with the hope for improved outcomes for patients with SSc-PH. PubMed. Curr Rheumatol Rep. 2013 Jan;15(1):302. (Also see: Prognosis in Systemic Sclerosis)
Pulmonary hypertension deaths and hospitalizations on the rise. Death rates throughout the reporting period 1990-2008 have been higher for blacks than for whites. In addition, a higher rate of hospitalization was observed in the Northeast than in other regions of the United States. MedicalXpress. 10/22/12.
Evidence For Pulmonary Arterial Hypertension (PAH) In Very Early And Mild Systemic Sclerosis (SSc). We found no evidence that PAH is a regular feature in this cohort of early/mild, profibrotic SSc patients. If confirmed in larger, multicenter studies, this finding has major impact on clinical practice, because regular, extensive screenings for PAH would not appear necessary in this patient population - in contrast to patients with established SSc. S. Jordan. EULAR 2011 SAT0444. Ann Rheum Dis 2011;70(Suppl3):667.

Functional Classification of Pulmonary Hypertension

Functional Classification of Severe Pulmonary Hypertension. The higher the class the more severe the disease and the greater the urgency for the patient to be accurately diagnosed and started on therapy for pulmonary hypertension. Pulmonary Hypertension RN.

Markers for Prognosis of Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) in patients with functional class II dyspnoea: mild symptoms but severe outcome. A majority of patients with mildly symptomatic SSc-PAH in New York Heart Association (NYHA) functional class (FC) II at diagnosis have a severe disease with poor prognosis. Eric Hachulla. Rheumatology. February 8, 2010.

Stories of Prognosis of Pulmonary Hypertension

Syl: Systemic Scleroderma/CREST/Pulmonary Hypertension/Sjögren's The physician's assistant noticed that my hands went really blue...
Tony B: Systemic Scleroderma with Pulmonary Fibrosis, Pulmonary Hypertension and Raynaud's It has taken me some time to come to terms with this disease...
 
Go to Pulmonary Hypertension Research Registries
About the ISN

This website is certified by Health On the Net Foundation. Click to verify.We are a full-service nonprofit 501(c)(3) providing stellar worldwide research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. This site complies with the HONcode standard for trustworthy health information: verify here.

 

Scleroderma Hotline (English Only)
Toll Free U.S. Call 1-800-564-7099
Direct Line: Call U.S. 952-831-3091

Post a message in Sclero Forums
Email: isn@sclero.org

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702
United States

AKA Scleroderma from A to Z and SCLERO.ORG
Privacy Policy, Financial Disclosure, and Disclaimer.

Home   Medical   News   Sclero Forums   Support   Translations

© Copyright 1998-2014 International Scleroderma Network
All Rights Reserved